Drugs / Ad4-Env145NFL
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06332339 | Mar 2024 → Nov 2026 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03878121 | Apr 2019 → Nov 2028 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad4-Env145NFL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03878121 ↗ |
| Modality | Vaccine | “The prime-boost vaccine regimens that include Ad4-Env145NFL and Trimer 4571 as heterologous boosts” NCT06332339 ↗ |
| Route | Intranasal | “10\^8 vp doses of Ad4-Env145NFL formulated as a liquid for intranasal administration.” NCT03878121 ↗ |